List of Excipients in Branded Drug TARGINIQ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Purdue Pharma LP	TARGINIQ	oxycodone hydrochloride/naloxone hydrochloride	59011-521	ETHYLCELLULOSES	1969-12-31
Purdue Pharma LP	TARGINIQ	oxycodone hydrochloride/naloxone hydrochloride	59011-521	FERRIC OXIDE RED	1969-12-31
Purdue Pharma LP	TARGINIQ	oxycodone hydrochloride/naloxone hydrochloride	59011-521	LACTOSE MONOHYDRATE	1969-12-31
Purdue Pharma LP	TARGINIQ	oxycodone hydrochloride/naloxone hydrochloride	59011-521	MAGNESIUM STEARATE	1969-12-31

TARGINIQ Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

TARGINIQ ER was an extended-release oxycodone hydrochloride and naloxone hydrochloride tablet developed by Purdue Pharma for chronic pain. Its commercial differentiation depended on abuse-deterrent performance, not on a novel active ingredient. The principal excipient opportunity is therefore a platform that preserves extended release, resists physical and chemical tampering, supports controlled-substance manufacturing, and remains bioequivalent under abbreviated regulatory pathways.

TARGINIQ ER received FDA approval in 2014 under NDA 208090. Its abuse-deterrent labeling described resistance to crushing, chewing, snorting, and injection relative to conventional oxycodone tablets. FDA later listed TARGINIQ ER as discontinued from marketing, with the discontinuation not attributed to safety or effectiveness concerns in the agency’s product database.[1,2]

What was TARGINIQ ER and how did its formulation work?

TARGINIQ ER combined oxycodone with naloxone in a controlled-release matrix. The product was intended to provide analgesia when taken orally as directed while reducing the attractiveness of tampering.

The formulation strategy had four technical objectives:

1. Deliver oxycodone over an extended period.
2. Maintain naloxone exposure sufficient to discourage parenteral or intranasal abuse.
3. Make the tablet difficult to crush into a readily abusable powder.
4. Produce a robust tablet that could be manufactured at commercial scale.

TARGINIQ ER was supplied in multiple strengths, including oxycodone/naloxone combinations such as 10/5 mg, 20/10 mg, 30/15 mg, and 40/20 mg, according to FDA labeling.[1]

What excipients were used in TARGINIQ ER?

The FDA prescribing information identifies a conventional but technically important excipient system. Reported inactive ingredients include components used for matrix formation, granulation, lubrication, coating, pigment, and tablet-process control.

Publicly identified excipient categories include:

Excipient category	Likely formulation role
Hypromellose	Hydrophilic release-control matrix
Ethylcellulose	Water-insoluble barrier and release moderation
Microcrystalline cellulose	Filler and compression aid
Lactose monohydrate	Filler and tablet-body contribution
Povidone	Binder
Crospovidone	Processing and structural control
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant
Polyvinyl alcohol, polyethylene glycol, and talc	Film-coating components
Titanium dioxide and iron oxide	Opacification and color
Sodium lauryl sulfate	Wetting or processing aid

The exact commercial value of these ingredients does not arise from their individual identity. Most are established pharmaceutical excipients. Value is created by their ratios, particle characteristics, processing sequence, matrix behavior, coating architecture, and interaction with the oxycodone-naloxone combination.

What excipient technology protected the TARGINIQ commercial proposition?

The core opportunity was an abuse-deterrent controlled-release matrix. The technical design likely relied on a combination of polymer swelling, gel formation, tablet hardness, and resistance to solvent extraction.

Abuse deterrence

FDA’s abuse-deterrent guidance evaluates whether a product meaningfully limits manipulation by physical, chemical, or thermal methods.[3] An excipient strategy for a TARGINIQ-type product must address several abuse routes:

• Crushing or milling into a powder
• Dissolution in water or alcohol
• Heating or smoking
• Snorting
• Injection
• Dose dumping in common beverages or solvents

A hydrophilic polymer such as hypromellose can form a viscous gel when hydrated. Ethylcellulose can reduce liquid penetration and slow drug diffusion. Together, the polymers can make the tablet difficult to convert into a low-viscosity injectable or readily insufflatable product.

The commercial challenge is balance. Excessive matrix strength can impair legitimate oral dissolution or create unacceptable food effects. Excessive water uptake can produce a gummy mass that remains susceptible to manipulation. The best formulation provides reproducible oral release while generating a high-viscosity, low-filterability dispersion after tampering.

Naloxone as a pharmacologic deterrent

Naloxone was not an excipient. It was the pharmacologic component supporting the abuse-deterrent concept. When the dosage form is taken orally, naloxone has limited systemic bioavailability because of extensive first-pass metabolism. When administered by a nonoral route, naloxone can antagonize opioid effects.

This design creates a formulation constraint: changes in excipients, coating, particle size, or release kinetics can alter the relative exposure of both active ingredients. A generic or follow-on product must therefore demonstrate more than oxycodone release similarity. It must control the oxycodone-to-naloxone exposure relationship across relevant conditions.

What formulation patents protected TARGINIQ and related oxycodone products?

TARGINIQ’s formulation protection was likely more important than protection for the active ingredients, which are long-established and off patent. Relevant rights may include patents covering:

• Controlled-release oxycodone and naloxone combinations
• Abuse-deterrent dosage forms
• Polymer matrices
• Tablet hardness and crush resistance
• Extraction-resistant formulations
• Manufacturing processes
• Methods of treating pain with oxycodone-naloxone products

The Orange Book does not provide a complete picture of the commercial formulation estate. It generally lists patents submitted by the NDA holder that claim the drug, formulation, method of use, or approved product. It does not capture every trade secret, process parameter, supplier specification, or unpublished manufacturing control.

What is the Orange Book status of TARGINIQ ER?

FDA’s Orange Book and Drugs@FDA records identify TARGINIQ ER under NDA 208090. The product’s marketing status is discontinued. A discontinued product may still have historical patent relevance, but the commercial impact depends on whether the NDA remains eligible for generic referencing, whether listed patents remain unexpired, and whether the product is commercially available.

For a follow-on applicant, the key regulatory questions are:

• Whether the reference product is eligible for an ANDA pathway.
• Whether FDA considers the reference product sufficiently available for comparative studies.
• Whether listed patents remain active.
• Whether the applicant must submit Paragraph IV certifications.
• Whether abuse-deterrent labeling can be obtained based on comparative studies.
• Whether the applicant can rely on the reference product’s inactive-ingredient framework or must establish a distinct formulation.

When did TARGINIQ lose exclusivity and what generic entry risks existed?

TARGINIQ’s regulatory exclusivity was separate from its patent protection. The 2014 approval would generally have provided five years of new chemical entity exclusivity only if the product qualified for that exclusivity. Because oxycodone and naloxone were previously approved active ingredients, the product’s regulatory exclusivity analysis could depend on the nature of the combination and FDA’s determination under the applicable statutory framework.

The primary long-term barrier was formulation and abuse-deterrent patent protection rather than active-ingredient exclusivity. Generic entry risks included:

Entry pathway	Main issue
Standard ANDA	Demonstrating bioequivalence to an extended-release combination
Paragraph IV ANDA	Challenging listed formulation or method patents
505(b)(2) application	Developing a modified oxycodone-naloxone product with reliance on FDA findings
Reformulated opioid	Establishing new abuse-deterrent properties and clinical utility
Competing opioid product	Substituting a different opioid or nonopioid therapy

A generic applicant could challenge the patents while designing around specific polymer ratios, coating materials, or process steps. That approach can reduce infringement risk but may create bioequivalence and abuse-deterrence problems.

Which excipient opportunities remain commercially attractive?

The strongest opportunities are not simple substitutions of lactose, magnesium stearate, or hypromellose. They are formulation platforms that improve measurable performance.

1. Crush-resistant opioid matrices

A supplier could develop a proprietary polymer blend that delivers:

• High tablet tensile strength
• Low friability
• Reduced particle generation after milling
• Controlled hydration
• Predictable dissolution after mechanical disruption

Commercial customers would include opioid manufacturers, contract development and manufacturing organizations, and companies developing abuse-deterrent products under 505(b)(2).

2. Solvent-resistant controlled-release systems

A high-value platform would limit oxycodone extraction in water, ethanol, acidic media, and alkaline media without materially changing oral pharmacokinetics.

Potential approaches include:

• Crosslinked hydrophilic polymers
• Hydrophobic polymer domains
• Ion-exchange resins
• Lipid-polymer matrices
• In situ gelling excipients
• Multiparticulate systems with tamper-resistant coatings

The regulatory burden is substantial because solvent-resistance claims require controlled laboratory testing and, for labeling, human abuse-potential studies under FDA guidance.[3]

3. Excipient systems for combination products

Oxycodone-naloxone products require synchronized release. A formulation that releases naloxone too quickly may impair oral tolerability. A formulation that releases it too slowly may weaken the deterrent effect. Excipient suppliers that can control differential release of two actives have a stronger commercial position than suppliers offering a single generic polymer.

4. Alcohol-resistant matrices

Dose dumping in the presence of alcohol is a key risk for extended-release opioids. A formulation that maintains release performance in hydroalcoholic media can support both safety positioning and product differentiation.

This opportunity extends beyond oxycodone. Similar technology can apply to hydromorphone, morphine, tapentadol, and other extended-release controlled substances.

5. Excipient packages for global markets

US abuse-deterrent labeling does not automatically translate into European or other-market approval. A global excipient package should support:

• United States FDA requirements
• European Pharmacopoeia and United States Pharmacopeia compliance
• Nitrosamine and elemental impurity control
• Low-peroxide excipient grades
• Consistent particle-size distribution
• Multiple manufacturing sites
• Supply continuity for controlled-substance products

Excipient vendors that can provide regulatory documentation, dual sourcing, and change-control support have a commercial advantage.

How does TARGINIQ compare with competing abuse-deterrent opioids?

TARGINIQ occupied a narrower position than single-ingredient abuse-deterrent oxycodone products because it combined opioid analgesia with naloxone.

Product	Active ingredients	Abuse-deterrent concept	Commercial implication
TARGINIQ ER	Oxycodone/naloxone	Physical and pharmacologic deterrence	Combination-product complexity
OXYCONTIN	Oxycodone	Physical and chemical resistance	Larger opioid franchise and broader commercial history
Troxyca ER	Oxycodone/naltrexone	Sequestered antagonist	Similar antagonist strategy with different active
Hysingla ER	Hydrocodone	Physical and chemical resistance	Competes in extended-release opioid treatment
Xtampza ER	Oxycodone	Microsphere-based abuse deterrence	Distinct formulation and food-effect profile

The most defensible excipient strategy depends on the target product. Matrix tablets may offer lower manufacturing complexity. Multiparticulate systems may provide better dose flexibility and tamper resistance but carry higher process and analytical costs.

What manufacturing and intellectual-property barriers affect a TARGINIQ follow-on?

The main barriers are process-specific.

Manufacturing barriers

A commercial product must control:

• Polymer hydration and viscosity
• Granule moisture
• Compression force
• Tablet tensile strength
• Coating weight gain
• Active uniformity
• Residual solvents
• Dissolution after crushing
• Performance in alcohol-containing media

Small process changes can alter release kinetics. Direct compression may reduce manufacturing steps but create segregation risk, especially when the active ingredients are present at different ratios. Wet granulation can improve content uniformity but may change polymer functionality.

Intellectual-property barriers

Potentially protectable elements include:

• Polymer ratios
• Specific molecular-weight grades
• Particle-size ranges
• Multi-layer tablet architecture
• Coating compositions
• Solvent-resistant matrix structures
• Compression and curing conditions
• Methods for reducing tampering
• Comparative release profiles

Trade secrets can be as important as patents. A competitor may be able to design around a patent but still face difficulty reproducing tablet robustness and dissolution behavior at scale.

Which companies could benefit from TARGINIQ-type excipient demand?

The opportunity spans several supplier categories:

• Functional polymer manufacturers
• Pharmaceutical excipient distributors
• Abuse-deterrent technology licensors
• Controlled-release formulation specialists
• Contract development and manufacturing organizations
• Analytical laboratories specializing in tamper-resistance testing
• Generic drug manufacturers with opioid portfolios

Potential strategic partners would favor excipients with established compendial status, low regulatory risk, global supply, and demonstrated performance in controlled-release dosage forms.

The most valuable licensing model would combine a proprietary excipient system with formulation know-how, process parameters, analytical methods, and regulatory support. A commodity excipient sale would generate lower switching costs and weaker customer retention.

What regulatory status and commercial risks should investors monitor?

TARGINIQ’s discontinued marketing status reduces the immediate value of a product-specific excipient strategy. The larger opportunity is a reusable abuse-deterrent platform applicable to other opioid products and controlled-release medicines.

Key commercial risks include:

• Declining prescription opioid volumes
• Public-policy pressure on opioid development
• High clinical and human-abuse-potential study costs
• Generic substitution
• Difficulty obtaining abuse-deterrent labeling
• Excipient supply interruptions
• Patent challenges
• Product liability exposure
• FDA scrutiny of comparative abuse-deterrent claims

The most attractive investment thesis is therefore platform-based. A company dependent solely on a TARGINIQ-specific reintroduction would face a limited addressable market. A company with a polymer system that supports multiple opioids, dose strengths, and delivery formats would have broader licensing potential.

What generic launch scenarios exist for TARGINIQ ER?

A generic launch could occur through several paths:

1. A conventional extended-release oxycodone-naloxone tablet with no abuse-deterrent claim.
2. An abuse-deterrent generic that matches the reference product’s formulation performance.
3. A 505(b)(2) product with a modified matrix or different antagonist.
4. A new opioid combination using a licensed abuse-deterrent platform.

The first path may face commercial disadvantages if payers, prescribers, or institutional buyers prefer abuse-deterrent labeling. The second path has the strongest differentiation but the highest development burden. The third path may provide greater formulation freedom but requires a more complex regulatory strategy.

Key Takeaways

• TARGINIQ ER was an oxycodone/naloxone extended-release tablet approved by FDA in 2014 under NDA 208090.
• Its commercial proposition depended on abuse-deterrent formulation performance and naloxone’s pharmacologic antagonism.
• The highest-value excipient opportunities involve polymer matrices, solvent resistance, crush resistance, alcohol-resistant release, and synchronized active release.
• Individual excipients are generally commodities; proprietary combinations, process controls, and performance data create defensible value.
• TARGINIQ is listed as discontinued from marketing, limiting the value of a product-specific strategy.
• A reusable abuse-deterrent platform for multiple controlled-release opioids offers stronger licensing and commercial potential.
• Generic entry would require careful analysis of Orange Book patents, Paragraph IV risks, bioequivalence, and whether abuse-deterrent labeling can be supported.
• Manufacturing know-how may remain commercially important even where patent protection has expired or is difficult to enforce.

FAQs

Can a new excipient combination obtain patent protection for a TARGINIQ-like product?

Yes. Protection may be available for novel polymer ratios, particle-size distributions, release profiles, tamper-resistance characteristics, coating systems, and manufacturing processes. The claims must satisfy novelty, nonobviousness, enablement, and written-description requirements.

Does an abuse-deterrent excipient automatically qualify a product for FDA abuse-deterrent labeling?

No. FDA labeling depends on evidence generated under the agency’s abuse-deterrent guidance. The formulation must be evaluated against relevant manipulation routes, and certain claims may require pharmacokinetic or human abuse-potential studies.[3]

Are naloxone and oxycodone required to release at the same rate?

Not necessarily. The formulation may use coordinated but nonidentical release kinetics. The design must preserve analgesic performance while maintaining the intended antagonist exposure after tampering.

Is a discontinued reference product still relevant to generic development?

Yes. FDA’s reference-product status, availability, Orange Book listings, patent certifications, and regulatory history remain relevant. A discontinued product can create practical development complications even when its active ingredients and historical patents are familiar.

What is the best commercial route for an excipient supplier entering the abuse-deterrent opioid market?

A platform licensing agreement is generally more defensible than selling a single commodity excipient. The package should include the excipient system, formulation know-how, manufacturing parameters, analytical methods, and regulatory support.

References

1. U.S. Food and Drug Administration. (2014). TARGINIQ ER prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: TARGINIQ ER, NDA 208090. FDA.

3. U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling. FDA.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

5. U.S. Pharmacopeial Convention. (2023). United States Pharmacopeia and National Formulary. USP.